ArriVent BioPharma (AVBP) director receives 13,562 stock options grant

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. director Parsey Merdad received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036.

The shares underlying this option vest on the first anniversary of the June 18, 2026 grant date, subject to his continued service through the vesting date. Following this award, he holds 13,562 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Parsey Merdad

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	13,562	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 13,562 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 13,562 options Exercise price: $31.74 per share Underlying shares: 13,562 shares +2 more

5 metrics

Option grant size 13,562 options Non-qualified stock option award on June 18, 2026

Exercise price $31.74 per share Strike price for non-qualified stock option

Underlying shares 13,562 shares Common stock underlying granted options

Expiration date June 17, 2036 Option term end date

Post-grant derivative holdings 13,562 options Total derivative securities following transaction

Key Terms

Non-Qualified Stock Option, exercise price, grant date, expiration date, +1 more

5 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

exercise price financial

"conversion_or_exercise_price: "31.7400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant date financial

"vest on the first anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

expiration date financial

"expiration_date: "2036-06-17T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 09:52 PM Accepted by SEC EDGAR 06/22/2026 - 09:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parsey Merdad

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD SUITE 100

(Street)

NEWTOWN SQUARE PENNSYLVANIA 19073

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$31.74	06/18/2026		A		13,562		06/18/2027(1)	06/17/2036	Common Stock	13,562	$0.00	13,562	D

Explanation of Responses:

1. The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

	By: /s/ James Kastenmayer, Attorney-in-Fact for: Merdad Parsey	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ArriVent BioPharma (AVBP) director Parsey Merdad report on this Form 4?

He reported receiving a grant of non-qualified stock options for 13,562 ArriVent BioPharma common shares. These options are a compensation award, not an open-market stock purchase or sale, and represent a new derivative holding.

What are the key terms of Parsey Merdad’s ArriVent (AVBP) stock options?

The options cover 13,562 shares of ArriVent common stock at an exercise price of $31.74 per share. They are non-qualified stock options that expire on June 17, 2036, providing a long-dated equity incentive.

When do Parsey Merdad’s ArriVent (AVBP) stock options vest?

The shares underlying this option vest on the first anniversary of the June 18, 2026 grant date. Vesting is conditioned on his continued service through the applicable vesting date, aligning incentives with ongoing tenure.

How many ArriVent (AVBP) derivative securities does Parsey Merdad hold after this grant?

After this award, he holds 13,562 derivative securities related to ArriVent common stock. This total equals the size of the new option grant, reflecting his directly held non-qualified stock options reported in the filing.

Was this ArriVent (AVBP) Form 4 an open-market stock purchase or sale?

No, the Form 4 reflects a grant or award acquisition of stock options, coded as “A.” It does not show any open-market buys or sells of ArriVent common stock by Parsey Merdad on the reported date.